ARDX — ARDELYX, INC.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1437402 ·
Last close
$3.18
Market Cap
$799.36M
52W High
$8.40
52W Low
$2.80
ADV30
4,760,461
Next earnings
2026-11-03

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 127,655,000 123,116,000 4,023,000 -737,000 587,525,000 46,317,000 423,479,000
Jun 2026 120,877,000 115,118,000 -12,425,000 -16,721,000 575,894,000 97,191,000 426,881,000
Mar 2026 94,473,000 89,662,000 -32,793,000 -37,605,000 504,507,000 31,209,000 355,885,000
Dec 2025 125,215,000 114,366,000 5,099,000 -407,000 501,604,000 67,999,000 334,655,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-15,514,000
Investing CF
$-37,562,000
Financing CF
$56,678,000
CapEx
$-599,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.22
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,002,002,000
Inventory
$24,440,000
Receivables
$93,441,000
ST Investments
$239,021,000
EBIT TTM
$-27,156,000
Pretax Income TTM
$-55,255,000
Interest Exp TTM
$28,099,000
Analysts
10

Yahoo Snapshot (yfinance, live)

Total Revenue
$468,220,000
EBITDA
$-33,035,000
Free Cash Flow
$33,018,124
Enterprise Value
$722,168,960
Total Cash
$285,337,984
Total Debt
$283,553,984
Shares Out
251,372,553
Trailing EPS
$-0.23
Book Value
$0.65
ROE
-34.9%
ROA
-4.2%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 407,320,000 -40,977,000 -61,599,000 501,604,000 334,655,000 166,949,000 -42,483,000
Dec 2024 333,615,000 -27,950,000 -39,136,000 435,754,000 262,465,000 173,289,000 -44,809,000
Dec 2023 124,456,000 -63,276,000 -66,067,000 297,579,000 130,763,000 166,816,000 -89,717,000
Dec 2022 52,158,000 -63,759,000 -67,207,000 190,066,000 91,737,000 98,329,000 -70,044,000

TTM Snapshot

Revenues TTM
$450,894,000
NetIncome TTM
$-55,702,000
OpCashFlow TTM
—
Assets (Latest)
$575,894,000
Forward EPS
$0.24

Max Pain — expiry 2027-01-15

max pain strike: $4.00 · spot: $3.12 · call oi: 19,884 · put oi: 186,937
Expected Move to 2027-01-15: ±$0.48 (15.22%) — implied range $2.64 – $3.59 · ATM straddle on $3.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
COLL COLLEGIUM PHARMACEUTICAL, INC $793.98M $25.55 —
IRWD IRONWOOD PHARMACEUTICALS INC $806.23M $4.87 —
LXRX LEXICON PHARMACEUTICALS, INC. $792.52M $1.78 —
RIGL RIGEL PHARMACEUTICALS INC $808.18M $42.92 —
SNDX Syndax Pharmaceuticals Inc $828.26M $9.20 —

News headlines (Yahoo Finance, 1h cache)

Ardelyx to Participate at the Jefferies Global Healthcare Conference in London
2026-11-10 12:30 · Yahoo
Ardelyx (ARDX) Stock Looks Cheap Relative To Its Sales Base
2026-11-04 22:16 · Yahoo
Ardelyx (ARDX) Results And IBSRELA Progress Put Its Valuation Story Back In Focus
2026-11-04 21:11 · Yahoo
Ardelyx: 3 Key Takeaways for Long-Term Investors
2026-11-04 15:27 · Yahoo
Ardelyx (ARDX) Q3 2026 Earnings Call Transcript
2026-11-04 15:00 · Yahoo
Ardelyx, Inc. Q3 2026 Earnings Call Summary
2026-11-04 13:30 · Yahoo
Ardelyx Inc (ARDX) (Q3 2026) Earnings Call Highlights: Revenue Climbs 19% as IBSRELA Shines and ...
2026-11-04 05:12 · Yahoo
What Ardelyx (ARDX) Said on Its Q3 Earnings Call
2026-11-04 00:14 · Yahoo
Ardelyx (ARDX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
2026-11-03 21:30 · Yahoo
Ardelyx: Q3 Earnings Snapshot
2026-11-03 21:19 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.